İlaç ilişkili Nörolojik Bozukluklar

Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22.

Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17(6):R264.

Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008;42(12):1843-50.

De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Curr Med Chem. 2001;8(4):371-84.

Akahane K, Tsutomi Y, Kimura Y, Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy. 1994;40(6):412-7.

Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother. 1989;33(10):1704-8.

Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo). 1995;48(5):408-16.

Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother. 1996;30(2):138-41.

Hoigne R, Schoch K. [Anaphylactic shock and acute nonallergic reactions following procaine-penicillin]. Schweiz Med Wochenschr. 1959;89:1350-6.

Graham JH, 3rd, Maher JR, Robinson SE. The effect of cocaine and other local anesthetics on central dopaminergic neurotransmission. J Pharmacol Exp Ther. 1995;274(2):707-17.

Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984;101(1):92-104.

Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129(Pt 5):1281-92.

Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. Epilepsia. 2000;41(7):887-94.

Vinton A, Kornberg AJ, Cowley M, Matkovic Z, Kilpatrick C, O'Brien TJ. Tiagabine-induced generalised non convulsive status epilepticus in patients with lesional focal epilepsy. J Clin Neurosci. 2005;12(2):128-33.

Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. Status epilepticus and tiagabine therapy revisited. Epilepsia. 2005;46(10):1625-32.

Nakken KO, Eriksson AS, Lossius R, Johannessen SI. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure. 2003;12(1):42-6.

Atefy R, Tettenborn B. Nonconvulsive status epilepticus on treatment with levetiracetam. Epilepsy Behav. 2005;6(4):613-6.

Panda S, Joshi SS. Paradoxical seizures and status epilepticus with newer antiepileptic drugs. Neurol India. 2011;59(3):479-80.

Steinhoff BJ, Stodieck SR. Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus. Seizure. 1993;2(3):261-5.

Capocchi G, Balducci A, Cecconi M, Pelli MA, Picchiarelli A, Silvestrelli G, et al. Valproate-induced epileptic tonic status. Seizure. 1998;7(3):237-41.

Velioğlu SK, Gazioğlu S. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2007;116(2):128-32.

Madi L, O'Brien AA, Fennell J. Status epilepticus secondary to fluoxetine. Postgrad Med J. 1994;70(823):383-4.

Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother. 1999;33(7-8):787-9.

Sinn DI, Chu K, Jung KH, Park KI, Nam H, Lee SK. Status epilepticus associated with sertindole. Eur J Neurol. 2007;14(8):e12-3.

Yip KK, Yeung WT. Lithium overdose causing non-convulsive status epilepticus--the importance of lithium levels and the electroencephalography in diagnosis. Hong Kong Med J. 2007;13(6):471-4.

Bellesi M, Passamonti L, Silvestrini M, Bartolini M, Provinciali L. Non-convulsive status epilepticus during lithium treatment at therapeutic doses. Neurol Sci. 2006;26(6):444-6.

Brown JW, Dunne JW, Fatovich DM, Lee J, Lawn ND. Amphetamine-associated seizures: clinical features and prognosis. Epilepsia. 2011;52(2):401-4.

Hall AP, Lyburn ID, Spears FD, Riley B. An unusual case of Ecstasy poisoning. Intensive Care Med. 1996;22(7):670-1.

Majlesi N, Shih R, Fiesseler FW, Hung O, Debellonio R. Cocaine-associated seizures and incidence of status epilepticus. West J Emerg Med. 2010;11(2):157-60.

Conway EE, Jr., Mezey AP, Powers K. Status epilepticus following the oral ingestion of cocaine in an infant. Pediatr Emerg Care. 1990;6(3):189-90.

Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381-93.

Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003;45(3):304-14.

Caksen H, Odabas D, Erol M, Anlar O, Tuncer O, Atas B. Do not overlook acute isoniazid poisoning in children with status epilepticus. J Child Neurol. 2003;18(2):142-3.

Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care. 2010;26(5):380-1.

Citak A, Soysal DD, Uçsel R, Karaböcüoglu M, Uzel N. Seizures associated with poisoning in children: tricyclic antidepressant intoxication. Pediatr Int. 2006;48(6):582-5.

Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci. 2011;18(3):313-8.

Mülhauser P, Allemann Y, Regamey C. Chloroquine and nonconvulsive status epilepticus. Ann Intern Med. 1995;123(1):76-7.

Connolly RM, Doherty CP, Beddy P, O'Byrne K. Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer. 2007;56(3):459-63.

Miller VS, Zwiener RJ, Fielman BA. Interferon-associated refractory status epilepticus. Pediatrics. 1994;93(3):511-2.

Kastrup O, Diener HC. Granulocyte-stimulating factor filgrastim and molgramostim induced recurring encephalopathy and focal status epilepticus. J Neurol. 1997;244(4):274-5.

Mut SE, Kutlu G, Ucler S, Erdal A, Inan LE. Reversible encephalopathy due to sulfasalazine. Clin Neuropharmacol. 2008;31(6):368-71.

Zakrzewski JL. Cyclosporin A-associated status epilepticus related to hematopoietic stem cell transplantation for thalassemia. Pediatr Hematol Oncol. 2003;20(6):481-6.

Junna MR, Rabinstein AA. Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry. 2007;78(12):1410-1.

Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci. 2014;45(3):222-5.

Feyissa AM, Tummala S. Ifosfamide related encephalopathy: the need for a timely EEG evaluation. J Neurol Sci. 2014;336(1-2):109-12.

Dunn DW, Parekh HU. Theophylline and status epilepticus in children. Neuropediatrics. 1991;22(1):24-6.

Mäkelä JP, Iivanainen M, Pieninkeroinen IP, Waltimo O, Lahdensuu M. Seizures associated with propofol anesthesia. Epilepsia. 1993;34(5):832-5.

de Gusmao CM, Ortega MR, Wallace DM. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2012;24(4):E47-8.

Zak R, Solomon G, Petito F, Labar D. Baclofen-induced generalized nonconvulsive status epilepticus. Ann Neurol. 1994;36(1):113-4.

Jang DH, Manini AF, Trueger NS, Duque D, Nestor NB, Nelson LS, et al. Status epilepticus and wide-complex tachycardia secondary to diphenhydramine overdose. Clin Toxicol (Phila). 2010;48(9):945-8.

Massey EW, Moon RE. Neurology and diving. Handb Clin Neurol. 2014;120:959-69.

Kandula T, Park SB, Cohn RJ, Krishnan AV, Farrar MA. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treat Rev. 2016;50:118-28.

Tay CG, Lee VWM, Ong LC, Goh KJ, Ariffin H, Fong CY. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2017;64(8).

Mora E, Smith EM, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016;6(11):2416-30.

Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil. 2013;94(8):1451-7.

Lavoie Smith EM, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015;20(1):37-46.

Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, et al. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2018;124(15):3220-30.

Kandula T, Farrar MA, Cohn RJ, Mizrahi D, Carey K, Johnston K, et al. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes. JAMA Neurol. 2018;75(8):980-8.

Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 2019;24 Suppl 2:S52-s62.

Liew WK, Pacak CA, Visyak N, Darras BT, Bousvaros A, Kang PB. Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. J Pediatr. 2016;178:227-32.

Islam B, Lustberg M, Staff NP, Kolb N, Alberti P, Argyriou AA. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 2019;24 Suppl 2:S63-s73.

Gomber S, Dewan P, Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr. 2010;77(1):97-100.

van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Crit Rev Oncol Hematol. 2017;114:114-30.

Sajdyk TJ, Boyle FA, Foran KS, Tong Y, Pandya P, Smith EML, et al. Obesity as a Potential Risk Factor for Vincristine-induced Peripheral Neuropathy. J Pediatr Hematol Oncol. 2020;42(7):e637-e40.

Bixby C CL, Weiss A, Koh WY, Li E. . Chemotherapy-induced peripheral neuropathy in pediatric patients: risk factors identified by retrospective review. Pediatr Blood Cancer 2017;64(s67).

Li T LL, Ren J, et al. (abstr). Superior outcomes in relapsed/refractory childhood B-ALL than adult patients with CD19 CAR-T cell therapy: a single-center pilot prospective study of 23 patients. Blood 2019;134:1353.

Bradfield SM, Sandler E, Geller T, Tamura RN, Krischer JP. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer. Pediatr Blood Cancer. 2015;62(6):1004-10.

Mokhtar GM, Shaaban SY, Elbarbary NS, Fayed WA. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hematol Oncol. 2010;32(8):594-600.

Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(7):1147-53.

Akbayram S, Akgun C, Doğan M, Sayin R, Caksen H, Oner AF. Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. Indian J Pediatr. 2010;77(6):681-3.

Tomasello C, Pinto RM, Mennini C, Conicella E, Stoppa F, Raucci U. Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: A preliminary study. Pediatr Blood Cancer. 2018;65(7):e27064.

Lavoie Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36(5):E49-60.

Gilchrist LS, Marais L, Tanner L. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer. 2014;22(2):359-66.

Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer. 2013;21(3):847-56.

Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932-7.

Reinders-Messelink HA, Van Weerden TW, Fock JM, Gidding CE, Vingerhoets HM, Schoemaker MM, et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol. 2000;4(5):225-33.

Johnston DL, Sung L, Stark D, Frazier AL, Rosenberg AR. A systematic review of patient-reported outcome measures of neuropathy in children, adolescents and young adults. Support Care Cancer. 2016;24(9):3723-8.

Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, et al. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016;24(12):5059-68.

Zuckner J. Drug-related myopathies. Rheum Dis Clin North Am. 1994;20(4):1017-32.

Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J. 1993;69(811):333-6.

Lane RJ, Mastaglia FL. Drug-induced myopathies in man. Lancet. 1978;2(8089):562-6.

Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve. 2003;27(2):142-56.

von Kemp K, Herregodts P, Duynslaeger L, Deleu D, Bruyland M, Cham B. Muscular fibrosis due to chronic intramuscular administration of narcotic analgesics. Acta Clin Belg. 1989;44(6):383-7.

Haller RG, Knochel JP. Skeletal muscle disease in alcoholism. Med Clin North Am. 1984;68(1):91-103.

Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982;61(3):141-52.

Martin F, Ward K, Slavin G, Levi J, Peters TJ. Alcoholic skeletal myopathy, a clinical and pathological study. Q J Med. 1985;55(218):233-51.

Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41(8):1235-9.

Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab. 1999;84(10):3515-21.

Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2 Pt 1):234-42.

Herzog AG. Proximal myopathy associated with inhaled steroids. Jama. 1999;281(1):37.

Askari A, Vignos PJ, Jr., Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. 1976;61(4):485-92.

Roth D, Alarcón FJ, Fernandez JA, Preston RA, Bourgoignie JJ. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med. 1988;319(11):673-7.

Herzlich BC, Arsura EL, Pagala M, Grob D. Rhabdomyolysis related to cocaine abuse. Ann Intern Med. 1988;109(4):335-6.

Pogue VA, Nurse HM. Cocaine-associated acute myoglobinuric renal failure. Am J Med. 1989;86(2):183-6.

Singhal PC, Rubin RB, Peters A, Santiago A, Neugarten J. Rhabdomyolysis and acute renal failure associated with cocaine abuse. J Toxicol Clin Toxicol. 1990;28(3):321-30.

Zamora-Quezada JC, Dinerman H, Stadecker MJ, Kelly JJ. Muscle and skin infarction after free-basing cocaine (crack). Ann Intern Med. 1988;108(4):564-6.

Parks JM, Reed G, Knochel JP. Cocaine-associated rhabdomyolysis. Am J Med Sci. 1989;297(5):334-6.

Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med. 1987;82(3):447-55.

Newton-Cheh C, Lin AE, Baggish AL, Wang H. Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. N Engl J Med. 2011;364(15):1450-60.

Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562-8.

Uri DS, Biavis M. Colchicine neuromyopathy. J Clin Rheumatol. 1996;2(3):163-6.

Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18(2):264-9.

van der Velden W, Huussen J, Ter Laak H, de Sévaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med. 2008;66(5):204-6.

Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.

Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality. Neurocrit Care. 2016;24(1):97-103.

Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-45.

Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998;19(1):73-82.

Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.

Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(2):187-94.

Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf. 2010;19(5):429-35.

Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. Cmaj. 2003;169(5):439-42.

Strawn JR, Keck PE, Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-6.

Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50(1):8-15.

Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol. 2003;18(4):301-9.

Desai D, Gupta K, Kumar R, Biswas A. Levosulpiride-induced neuroleptic malignant syndrome in rheumatoid arthritis. BMJ Case Rep. 2018;2018.

Pope HG, Jr., Aizley HG, Keck PE, Jr., McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry. 1991;52(5):208-12.

Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182(3):168-73.

Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry. 2000;41(1):73-5.

Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146(6):717-25.

Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry. 1998;44(6):499-507.

Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010;64(1):79-87.

Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012;73(4):427-30.

Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-20.

Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. Cmaj. 2003;168(11):1439-42.

Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79(4):201-9.

Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219-23.

Canan F, Korkmaz U, Kocer E, Onder E, Yildirim S, Ataoglu A. Serotonin syndrome with paroxetine overdose: a case report. Prim Care Companion J Clin Psychiatry. 2008;10(2):165-7.

Fugate JE, White RD, Rabinstein AA. Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series. Resuscitation. 2014;85(6):774-7.

Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763-83.

Ganetsky M BE. Serotonin syndrome—what have we learned? clinical pediatric emergency medicine. 2005;6.

Malek N, Baker MR. Common toxidromes in movement disorder neurology. Postgrad Med J. 2017;93(1100):326-32.

Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. Psychiatr Clin North Am. 2016;39(3):391-411.

Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord. 2014;20 Suppl 1:S108-12.

Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr. 2019;42(2):56-61.

Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011;26(5):237-42.

Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20(3):322-34.

Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES. Acta Psychiatr Scand. 1964;40(1):10-27.

Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry. 2001;62(12):967-74.

Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):835-43.

Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr. 1973;3(3):247-53.

Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol. 2015;6:75.

Lappin JM, Darke S, Farrell M. Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug Alcohol Depend. 2018;187:134-40.

Shi Y, Hu D, Rodgers EL, Katusic SK, Gleich SJ, Hanson AC, et al. Epidemiology of general anesthesia prior to age 3 in a population-based birth cohort. Paediatr Anaesth. 2018;28(6):513-9.

Vutskits L, Gascon E, Tassonyi E, Kiss JZ. Clinically relevant concentrations of propofol but not midazolam alter in vitro dendritic development of isolated gamma-aminobutyric acid-positive interneurons. Anesthesiology. 2005;102(5):970-6.

Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003;23(3):876-82.

Jevtovic-Todorovic V. Exposure of Developing Brain to General Anesthesia: What Is the Animal Evidence? Anesthesiology. 2018;128(4):832-9.

Vutskits L, Xie Z. Lasting impact of general anaesthesia on the brain: mechanisms and relevance. Nat Rev Neurosci. 2016;17(11):705-17.

Communication FDS. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women 2017 [Available from: https:// www.fda.gov/Drugs/DrugSafety/ucm532356.htm. .

Slikker W, Jr., Zou X, Hotchkiss CE, Divine RL, Sadovova N, Twaddle NC, et al. Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol Sci. 2007;98(1):145-58.

Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, Martin LD, et al. Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. Anesthesiology. 2012;116(2):372-84.

Paule MG, Li M, Allen RR, Liu F, Zou X, Hotchkiss C, et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol. 2011;33(2):220-30.

Shen X, Dong Y, Xu Z, Wang H, Miao C, Soriano SG, et al. Selective anesthesia-induced neuroinflammation in developing mouse brain and cognitive impairment. Anesthesiology. 2013;118(3):502-15.

Sinner B, Friedrich O, Zink W, Zausig Y, Graf BM. The toxic effects of s(+)-ketamine on differentiating neurons in vitro as a consequence of suppressed neuronal Ca2+ oscillations. Anesth Analg. 2011;113(5):1161-9.

Lee BH, Chan JT, Kraeva E, Peterson K, Sall JW. Isoflurane exposure in newborn rats induces long-term cognitive dysfunction in males but not females. Neuropharmacology. 2014;83:9-17.

Lepousé C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006;96(6):747-53.

Card E, Pandharipande P, Tomes C, Lee C, Wood J, Nelson D, et al. Emergence from general anaesthesia and evolution of delirium signs in the post-anaesthesia care unit. Br J Anaesth. 2015;115(3):411-7.

Jacob Z, Li H, Makaryus R, Zhang S, Reinsel R, Lee H, et al. Metabolomic profiling of children's brains undergoing general anesthesia with sevoflurane and propofol. Anesthesiology. 2012;117(5):1062-71.

Holzgrafe RE, Vondrell JJ, Mintz SM. Reversal of postoperative reactions to scopolamine with physostigmine. Anesth Analg. 1973;52(6):921-5.

Hammon K, DeMartino BK. Postoperative delirium secondary to atropine premedication. Anesth Prog. 1985;32(3):107-8.

Kongsrud F, Sponheim S. A comparison of atropine and glycopyrrolate in anaesthetic practice. Acta Anaesthesiol Scand. 1982;26(6):620-5.

Vlajkovic GP, Sindjelic RP. Emergence delirium in children: many questions, few answers. Anesth Analg. 2007;104(1):84-91.

Quincke H. Ueber Meningitis serosa und verwandte Zustände. Deutsche Zeitschrift für Nervenheilkunde. 1896;9(3-4):149-68.

Aylward SC, Waslo CS, Au JN, Tanne E. Manifestations of Pediatric Intracranial Hypertension From the Intracranial Hypertension Registry. Pediatr Neurol. 2016;61:76-82.

Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr. 2010;74(6):381-9.

Binder DK, Horton JC, Lawton MT, McDermott MW. Idiopathic intracranial hypertension. Neurosurgery. 2004;54(3):538-51; discussion 51-2.

Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol. 1992;37(3):155-66.

Phillips PH, Repka MX, Lambert SR. Pseudotumor cerebri in children. J aapos. 1998;2(1):33-8.

Avery RA, Shah SS, Licht DJ, Seiden JA, Huh JW, Boswinkel J, et al. Reference range for cerebrospinal fluid opening pressure in children. N Engl J Med. 2010;363(9):891-3.

Lee MW, Vedanarayanan VV. Cerebrospinal fluid opening pressure in children: experience in a controlled setting. Pediatr Neurol. 2011;45(4):238-40.

Kaiser AM, Whitelaw AG. Normal cerebrospinal fluid pressure in the newborn. Neuropediatrics. 1986;17(2):100-2.

Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-65.

Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol. 1998;126(1):116-21.

Kushida A, Tamura H. Retinoic acids induce neurosteroid biosynthesis in human glial GI-1 Cells via the induction of steroidogenic genes. J Biochem. 2009;146(6):917-23.

Warner JE, Bernstein PS, Yemelyanov A, Alder SC, Farnsworth ST, Digre KB. Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. Ann Neurol. 2002;52(5):647-50.

Lombaert A, Carton H. Benign intracranial hypertension due to A-hypervitaminosis in adults and adolescents. Eur Neurol. 1976;14(5):340-50.